Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Bruno, Gori"'
Publikováno v:
Clinical Management Issues, Vol 4, Iss 1S, Pp 3-7 (2015)
We report the case of a 51-year-old woman with limited Small Cell Lung Cancer (SCLC). Cytological diagnosis has been made by fibroscopy. Chemotherapy schedule was cisplatin 30 mg/mq and VP-16 100 mg/mq days 1,2,3 q21 as first line treatment. The seru
Externí odkaz:
https://doaj.org/article/b25af28d89884b4b849884a47f771108
Publikováno v:
Clinical Management Issues, Vol 3, Iss 2, Pp 63-69 (2009)
We report the case of a 53-year-old woman with brain metastatic Non-Small Cell Lung Cancer (NSCLC). Diagnosis was made during brain surgery. Brain metastases were treated both with surgery and radiotherapy. The chemotherapy schedule was cisplatin 75
Externí odkaz:
https://doaj.org/article/7b6a7d562f574e438fb6436bb9ab7b8f
Autor:
Chiara D’Antonio, Antonio Passaro, Bruno Gori, Ester Del Signore, Maria Rita Migliorino, Serena Ricciardi, Alberto Fulvi, Filippo de Marinis
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 6 (2014)
Bone and brain metastases are a very common secondary localization of disease in patients with lung cancer. The prognosis of these patients is still poor with a median survival of less than 1 year. Current therapeutic approaches include palliative ra
Externí odkaz:
https://doaj.org/article/4491e78d56c544588c4a9a2dc724957b
Autor:
Alvaro Leone, Filippo de Marinis, Rita Gasbarra, Paolo Graziano, Giuseppe Pelosi, Stefano De Santis, Bruno Gori, Rita Migliorino
Publikováno v:
Journal of Clinical Oncology. 33:e115-e118
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60004f9f64e0348fc98501bbbe804405
https://doi.org/10.1200/jco.2013.49.5697
https://doi.org/10.1200/jco.2013.49.5697
Autor:
Salvatore Intagliata, Serena Ricciardi, Alberto Fulvi, Bruno Gori, Ester Del Signore, Filippo de Marinis
Publikováno v:
Therapeutics and Clinical Risk Management
Lung cancer is the leading cause of mortality worldwide. Non-small cell lung cancer (NSCLC) is a particularly aggressive cancer, the optimum management of which is still being determined. In the metastatic disease, the standard therapy is a platinum-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80bce0e6deba38aeec9eba4686e0b3e3
http://europepmc.org/articles/PMC3253753
http://europepmc.org/articles/PMC3253753
Autor:
Bruno Gori, Goffredo Serra, Francesco Fraioli, M. Mennini, Carlo Catalano, Flavia Longo, Fulvio Zaccagna, Roberto Passariello, Michele Anzidei
Publikováno v:
Radiology. 259:574-582
Purpose: To determine whether wide-volume perfusion computed tomography (CT) performed with a new generation scanner can allow evaluation of the effects of chemotherapy combined with antiangiogenetic treatment on the whole tumor mass in patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ee02a4dce322a0eab2df5bc9d63bbc8
https://doi.org/10.1148/radiol.11100600
https://doi.org/10.1148/radiol.11100600
Publikováno v:
Clinical Management Issues; Vol 4, No 1S (2010); 3-7
Clinical Management Issues, Vol 4, Iss 1S, Pp 3-7 (2015)
Clinical Management Issues, Vol 4, Iss 1S, Pp 3-7 (2015)
We report the case of a 51-year-old woman with limited Small Cell Lung Cancer (SCLC). Cytological diagnosis has been made by fibroscopy. Chemotherapy schedule was cisplatin 30 mg/mq and VP-16 100 mg/mq days 1,2,3 q21 as first line treatment. The seru
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ff979c754fc7e33e3bc7849d3a50475
https://journals.seedmedicalpublishers.com/index.php/cmi/article/view/1064
https://journals.seedmedicalpublishers.com/index.php/cmi/article/view/1064
Autor:
Filippo de Marinis, Chiara D'Antonio, Alberto Fulvi, Antonio Passaro, Ester Del Signore, Serena Ricciardi, Maria Rita Migliorino, Bruno Gori
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 6 (2014)
Bone and brain metastases are a very common secondary localization of disease in patients with lung cancer. The prognosis of these patients is still poor with a median survival of less than 1 year. Current therapeutic approaches include palliative ra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3dd34ecf4387f61060d55460bd53199
https://europepmc.org/articles/PMC3987652/
https://europepmc.org/articles/PMC3987652/
Publikováno v:
Clinical lung cancer. 15(4)
Nonhematologic toxicities are frequently observed in patients receiving epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in advanced non-small-cell lung cancer (NSCLC).For the 2010-2013 period, the authors evaluated 158 patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::119d0923534260b88300c97660e555c8
https://pubmed.ncbi.nlm.nih.gov/24954231
https://pubmed.ncbi.nlm.nih.gov/24954231
Publikováno v:
Future oncology (London, England). 8(5)
Non-small-cell lung cancer is a particularly aggressive cancer. Combination chemotherapy remains the standard therapy for patients with advanced or metastatic disease. However, despite the available treatment options for patients who progress beyond
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41ab6c7adf49caeca8dddf8e6acdeecc
https://pubmed.ncbi.nlm.nih.gov/22646771
https://pubmed.ncbi.nlm.nih.gov/22646771